HUTCHMED DRC

NASDAQ HCM

Data sourced from

and

Download Data

HUTCHMED DRC Average Collection Period 3 year CAGR for the year ending December 31, 2023: -16.84%

HUTCHMED DRC Average Collection Period 3 year CAGR is -16.84% for the year ending December 31, 2023, a -231.02% change year over year. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

HUTCHMED DRC Average Collection Period for the year ending December 31, 2022 was 107.08, a 26.93% change year over year.
HUTCHMED DRC Average Collection Period for the year ending December 31, 2021 was 84.36, a 39.03% change year over year.
HUTCHMED DRC Average Collection Period for the year ending December 31, 2020 was 60.68, a -18.56% change year over year.
HUTCHMED DRC Average Collection Period for the year ending December 31, 2019 was 74.51, a -10.31% change year over year.

NASDAQ: HCM

HUTCHMED DRC

CEO	Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA
IPO Date	March 17, 2016
Location	Hong Kong
Headquarters	Cheung Kong Center, Central, Hong Kong
Employees	1,988
Sector	Healthcare
Industry	Drug manufacturers - specialty & generic

Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Key trends